Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:7497 |
Name | brain ependymoma |
Definition | A brain glioma that is characterized by tumor of the ependyma, has_material_basis_in abnormally proliferating cells derives_from ependymal cells, located_in spine in adults and located_in intracranial (4th ventricle) in children. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer brain glioma brain ependymoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01096368 | Phase III | Carboplatin + Cyclophosphamide + Vincristine sulfate liposome Carboplatin + Etoposide + Vincristine sulfate liposome Cisplatin + Cyclophosphamide + Etoposide Cisplatin + Cyclophosphamide + Etoposide + Vincristine sulfate liposome | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
NCT01295944 | Phase II | Bevacizumab + Carboplatin | Carboplatin and Bevacizumab for Recurrent Ependymoma | Completed | USA | 0 |
NCT02458339 | Phase I | Methotrexate | Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors | Completed | USA | 0 |
NCT03434262 | Phase I | Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | Completed | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03727841 | Phase II | Marizomib | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | Terminated | USA | 0 |
NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | SWE | NLD | FRA | DEU | CHE | AUT | AUS | 0 |
NCT04732065 | Phase I | ONC206 | ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023) | Recruiting | USA | CHE | 0 |
NCT04903080 | Phase I | HER2 CAR-T cells | HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma | Recruiting | USA | 0 |
NCT04958486 | Phase I | Azacitidine + Trastuzumab | Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma | Completed | USA | 0 |
NCT05106296 | Phase I | Cyclophosphamide + Etoposide + Ibrutinib + Indoximod | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | Recruiting | USA | 0 |
NCT05169944 | Phase I | Hu5F9-G4 | Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025) | Completed | USA | 0 |
NCT05887882 | Phase I | TGF-beta-imprinted NK cells | Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors (PNOC028) | Recruiting | USA | 0 |